| 2019-11-04 08:30:08|
CBAY 08:30 11/04 11/04/19
CymaBay reaches target enrollment in ENHANCE global Phase 3 study
CymaBay Therapeutics announced achievement of the targeted 240 patient enrollment goal for ENHANCE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary Cholangitis. CymaBay is on track to complete full enrollment by the end of November. With more than 240 patients enrolled, ENHANCE is CymaBay's lead regulatory registration study evaluating the safety and efficacy of its investigational drug, seladelpar, for patients already diagnosed with PBC who have been using ursodeoxycholic acid, but have not achieved the recommended treatment goal or cannot tolerate UDCA. ENHANCE is a 52-week, placebo-controlled, randomized study conducted in over 20 countries.